Comorbidities in lung cancer

Prevalence, severity and links with socioeconomic status and treatment

Derek Grose*, David S. Morrison, Graham Devereux, Richard Jones, Dave Sharma, Colin Selby, Kirsty Docherty, David McIntosh, Greig Louden, Marianne Nicolson, Donald C. McMillan, Robert Milroy

*Corresponding author for this work

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background Survival from lung cancer remains poor in Scotland, UK. Although the presence of comorbidities is known to influence outcomes, detailed quantification of comorbidities is not available in routinely collected audit or cancer registry data. The aim of the present study was to assess the prevalence and severity of comorbidities in patients with newly diagnosed lung cancer across four centres throughout Scotland using validated criteria. Methods Between 2005 and 2008, all patients with newly diagnosed lung cancer coming through the multidisciplinary teams in four Scottish centres were included in the study. Patient demographics, WHO/ Eastern Cooperative Oncology Group performance status, clinicopathological features and primary treatment modality were recorded. Results Details of 882 patients were collected prospectively. The majority of patients (87.3%) had at least one comorbidity, the most common being weight loss (53%), chronic obstructive pulmonary disease (43%), renal impairment (28%) and ischaemic heart disease (27%). A composite score was produced that included both number and severity of comorbidities. One in seven patients (15.3%) had severe comorbidity scores. There were statistically significant variations in comorbidity scores between treatment centres and between non-small cell lung carcinoma treatment groups. Disease stage was not associated with comorbidity score. Conclusions There is a high prevalence of multiple, severe comorbidities in Scottish patients with lung cancer, and these vary by site and treatment group. Further research is needed to determine the relationship between comorbidity scores and survival in these patients.

Original languageEnglish
Pages (from-to)305-310
Number of pages6
JournalPostgraduate Medical Journal
Volume90
Issue number1064
Early online date27 Mar 2014
DOIs
Publication statusPublished - Jun 2014

Fingerprint

Social Class
Comorbidity
Lung Neoplasms
Therapeutics
Scotland
Survival
Non-Small Cell Lung Carcinoma
Chronic Obstructive Pulmonary Disease
Myocardial Ischemia
Registries
Weight Loss
Demography
Kidney
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comorbidities in lung cancer : Prevalence, severity and links with socioeconomic status and treatment. / Grose, Derek; Morrison, David S.; Devereux, Graham; Jones, Richard; Sharma, Dave; Selby, Colin; Docherty, Kirsty; McIntosh, David; Louden, Greig; Nicolson, Marianne; McMillan, Donald C.; Milroy, Robert.

In: Postgraduate Medical Journal, Vol. 90, No. 1064, 06.2014, p. 305-310.

Research output: Contribution to journalArticle

Grose, D, Morrison, DS, Devereux, G, Jones, R, Sharma, D, Selby, C, Docherty, K, McIntosh, D, Louden, G, Nicolson, M, McMillan, DC & Milroy, R 2014, 'Comorbidities in lung cancer: Prevalence, severity and links with socioeconomic status and treatment', Postgraduate Medical Journal, vol. 90, no. 1064, pp. 305-310. https://doi.org/10.1136/postgradmedj-2013-132186
Grose, Derek ; Morrison, David S. ; Devereux, Graham ; Jones, Richard ; Sharma, Dave ; Selby, Colin ; Docherty, Kirsty ; McIntosh, David ; Louden, Greig ; Nicolson, Marianne ; McMillan, Donald C. ; Milroy, Robert. / Comorbidities in lung cancer : Prevalence, severity and links with socioeconomic status and treatment. In: Postgraduate Medical Journal. 2014 ; Vol. 90, No. 1064. pp. 305-310.
@article{02029aba52514500b1858d5bfa0b3e73,
title = "Comorbidities in lung cancer: Prevalence, severity and links with socioeconomic status and treatment",
abstract = "Background Survival from lung cancer remains poor in Scotland, UK. Although the presence of comorbidities is known to influence outcomes, detailed quantification of comorbidities is not available in routinely collected audit or cancer registry data. The aim of the present study was to assess the prevalence and severity of comorbidities in patients with newly diagnosed lung cancer across four centres throughout Scotland using validated criteria. Methods Between 2005 and 2008, all patients with newly diagnosed lung cancer coming through the multidisciplinary teams in four Scottish centres were included in the study. Patient demographics, WHO/ Eastern Cooperative Oncology Group performance status, clinicopathological features and primary treatment modality were recorded. Results Details of 882 patients were collected prospectively. The majority of patients (87.3{\%}) had at least one comorbidity, the most common being weight loss (53{\%}), chronic obstructive pulmonary disease (43{\%}), renal impairment (28{\%}) and ischaemic heart disease (27{\%}). A composite score was produced that included both number and severity of comorbidities. One in seven patients (15.3{\%}) had severe comorbidity scores. There were statistically significant variations in comorbidity scores between treatment centres and between non-small cell lung carcinoma treatment groups. Disease stage was not associated with comorbidity score. Conclusions There is a high prevalence of multiple, severe comorbidities in Scottish patients with lung cancer, and these vary by site and treatment group. Further research is needed to determine the relationship between comorbidity scores and survival in these patients.",
author = "Derek Grose and Morrison, {David S.} and Graham Devereux and Richard Jones and Dave Sharma and Colin Selby and Kirsty Docherty and David McIntosh and Greig Louden and Marianne Nicolson and McMillan, {Donald C.} and Robert Milroy",
year = "2014",
month = "6",
doi = "10.1136/postgradmedj-2013-132186",
language = "English",
volume = "90",
pages = "305--310",
journal = "Postgraduate Medical Journal",
issn = "0032-5473",
publisher = "BMJ Publishing Group",
number = "1064",

}

TY - JOUR

T1 - Comorbidities in lung cancer

T2 - Prevalence, severity and links with socioeconomic status and treatment

AU - Grose, Derek

AU - Morrison, David S.

AU - Devereux, Graham

AU - Jones, Richard

AU - Sharma, Dave

AU - Selby, Colin

AU - Docherty, Kirsty

AU - McIntosh, David

AU - Louden, Greig

AU - Nicolson, Marianne

AU - McMillan, Donald C.

AU - Milroy, Robert

PY - 2014/6

Y1 - 2014/6

N2 - Background Survival from lung cancer remains poor in Scotland, UK. Although the presence of comorbidities is known to influence outcomes, detailed quantification of comorbidities is not available in routinely collected audit or cancer registry data. The aim of the present study was to assess the prevalence and severity of comorbidities in patients with newly diagnosed lung cancer across four centres throughout Scotland using validated criteria. Methods Between 2005 and 2008, all patients with newly diagnosed lung cancer coming through the multidisciplinary teams in four Scottish centres were included in the study. Patient demographics, WHO/ Eastern Cooperative Oncology Group performance status, clinicopathological features and primary treatment modality were recorded. Results Details of 882 patients were collected prospectively. The majority of patients (87.3%) had at least one comorbidity, the most common being weight loss (53%), chronic obstructive pulmonary disease (43%), renal impairment (28%) and ischaemic heart disease (27%). A composite score was produced that included both number and severity of comorbidities. One in seven patients (15.3%) had severe comorbidity scores. There were statistically significant variations in comorbidity scores between treatment centres and between non-small cell lung carcinoma treatment groups. Disease stage was not associated with comorbidity score. Conclusions There is a high prevalence of multiple, severe comorbidities in Scottish patients with lung cancer, and these vary by site and treatment group. Further research is needed to determine the relationship between comorbidity scores and survival in these patients.

AB - Background Survival from lung cancer remains poor in Scotland, UK. Although the presence of comorbidities is known to influence outcomes, detailed quantification of comorbidities is not available in routinely collected audit or cancer registry data. The aim of the present study was to assess the prevalence and severity of comorbidities in patients with newly diagnosed lung cancer across four centres throughout Scotland using validated criteria. Methods Between 2005 and 2008, all patients with newly diagnosed lung cancer coming through the multidisciplinary teams in four Scottish centres were included in the study. Patient demographics, WHO/ Eastern Cooperative Oncology Group performance status, clinicopathological features and primary treatment modality were recorded. Results Details of 882 patients were collected prospectively. The majority of patients (87.3%) had at least one comorbidity, the most common being weight loss (53%), chronic obstructive pulmonary disease (43%), renal impairment (28%) and ischaemic heart disease (27%). A composite score was produced that included both number and severity of comorbidities. One in seven patients (15.3%) had severe comorbidity scores. There were statistically significant variations in comorbidity scores between treatment centres and between non-small cell lung carcinoma treatment groups. Disease stage was not associated with comorbidity score. Conclusions There is a high prevalence of multiple, severe comorbidities in Scottish patients with lung cancer, and these vary by site and treatment group. Further research is needed to determine the relationship between comorbidity scores and survival in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84901342286&partnerID=8YFLogxK

U2 - 10.1136/postgradmedj-2013-132186

DO - 10.1136/postgradmedj-2013-132186

M3 - Article

VL - 90

SP - 305

EP - 310

JO - Postgraduate Medical Journal

JF - Postgraduate Medical Journal

SN - 0032-5473

IS - 1064

ER -